Current management of purpura fulminans: A multicenter study

Journal of Burn Care and Rehabilitation

Volumn 24, Issue 3, 2003, Pages 119-126

  Warner, Petra M ^a,b   Kagan, R J ^a,b   Yakuboff, K P ^a,b   Kemalyan, N ^c   Palmieri, T L ^d   Greenhalgh, D G ^d   Sheridan, R L ^e   Mozingo, D W ^f   Heimbach, D M ^g   Gibran, N S ^g   Engrav, L ^g   Saffle, J R ^h   Edelman, L S ^h   Warden, G D ^a,b,h  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Emmuanuel Hospital   (United States)

^d SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^e SHRINERS HOSPITALS FOR CHILDREN   (United States)

^f UNIVERSITY OF FLORIDA HEALTH   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; MAFENIDE; NITROPRUSSIDE SODIUM; PROTEIN C; SULFADIAZINE SILVER; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGED; AMPUTATION; ANTIBIOTIC THERAPY; ASSISTED VENTILATION; BURN; CHILD; CLINICAL FEATURE; COMORBIDITY; CORTICOSTEROID THERAPY; FASCIOTOMY; FEMALE; FLUID THERAPY; FULMINATING PURPURA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; RESUSCITATION; REVIEW; SKIN GRAFT; SKIN NECROSIS; STREPTOCOCCUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BACTEREMIA; BURNS; CHILD; CHILD, PRESCHOOL; FASCIITIS, NECROTIZING; HUMANS; INFANT; INFANT, NEWBORN; MEDICAL RECORDS; MENINGOCOCCAL INFECTIONS; PURPURA, SCHOENLEIN-HENOCH; RETROSPECTIVE STUDIES; SOFT TISSUE INJURIES; STREPTOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0038248000     PISSN: 02738481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.BCR.0000066789.79129.C2     Document Type: Review

References (29)

1. Brown DL, Greenhalgh DG, Warden GD. Purpura fulminans: a disease best managed in a bum center. J Burn Care Rehabil 1998;19:119-23.
2. Olivares R, Bouyer J, Hubert B. Risk factors for death in meningococcal disease. Pathol Biol 1993;41:164-8.
3. Herrera R, Hobar PC, Ginsburg CM. Surgical intervention for the complications of meningococcal-induced purpura fulminans. Pediatr Infect Dis J 1994;13:734-7.
4. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
5. Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat Quart 1997;50:170-6.
6. Powars D, Larsen R, Johnson J, et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993;17:254-61.
7. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk Factors for Meningococcal Disease in College Students. JAMA 2001;286:688-93.
8. Faust SN, Levin M, Harrison B, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
9. Weisel G, Joyce D, Gutmundsdottir A, Shasby DM. Human recombinant activated protein C in meningococcal sepsis. Chest 2002;121:292-5.
10. Alberio L, Lammle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 2001;32:1338-46.
11. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and hemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
12. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719-24.
13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
14. Kennedy NJ, Duncan AW. Acute meningococcemia: recent advances in management (with particular reference to children) [review]. Anaesth Intensive Care 1996;24:197-216.
15. Geiman BJ, Smith AL. Dexamethasone and bacterial meningitis. A meta-analysis of randomized controlled trials. West J Med 1992;157:27-31.
16. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997;278:925-31.
17. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65.
18. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
19. Lefering R, Neugebauer EA. Steroid Controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23: 1294-303.
20. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single center study. Crit Care Med 1999;27:723-32.
21. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984;311: 1137-43.
22. Briegel J, Kellerman W, Frost H, et al. Low dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The phospholipase A2 study group. Clin Invest 1994;72:782-7.
23. Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29:S117-20.
24. Van Woensel JB, Biezeveld MH, Alders AM, et al. Adrenocorticotropic hormone and cortisol levels in relation to inflammatory response and disease severity in children with meningococcal disease. J Infect Dis 2001;184:1532-7.
25. Cohen JR, Lackner R, Keller A, Douglas B. The surgical implications of purpura fulminans. Ann Vasc Surg 1990;4: 276-9.
26. Chu DZJ, Blaisdell FW. Purpura fulminans. Am J Surg 1982; 143:356-62.
27. Seagle MB, Bingham HG. Purpura fulminans. Ann Plast Surg 1988;20:576-81.
28. Silbart S, Oppenheim W. Purpura fulminans. Medical, surgical, and rehabilitative considerations. Clin Orthop 1985; 193:206-13.
29. Sheridan RL, Briggs SE, Remensnyder JP, Tompkins RG. Management strategy in purpura fulminans with multiple organ failure in children. Burns 1996;22:53-6.